| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,200,000 |
| Market
Cap: |
9.43(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.463 - $1.47 |
|
| Level
I Sector: |
Conglomerates |
| Level
II Sector: |
Conglomerates |
| Level
III Sector: |
Conglomerates |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Co.'s sufentanil sublingual products and product candidates include DSUVIA®, which is indicated for use in adults in supervised healthcare settings; Zalviso®, which is intended for the management of moderate-to-severe acute pain in hospitalized adult patients; and ARX-02, which is for cancer breakthrough pain in opioid-tolerant patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,000 |
20,000 |
66,400 |
| Total Buy Value |
$0 |
$7,268 |
$15,218 |
$25,551 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
2 |
3 |
| Total Shares Sold |
0 |
0 |
16,956 |
16,956 |
| Total Sell Value |
$0 |
$0 |
$19,235 |
$19,235 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
2 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Palmer Pamela P |
Chief Medical Officer |
• – – |
2018-08-06 |
4 |
B |
$2.75 |
$101,750 |
D/D |
37,000 |
456,134 |
2.74 |
- |
|
| Asadorian Raffi |
Chief Financial Officer |
• – – |
2018-08-06 |
4 |
B |
$2.75 |
$13,725 |
D/D |
5,000 |
32,000 |
2.74 |
- |
|
| Edwards Mark G |
Director |
– • – |
2018-06-05 |
4 |
B |
$3.35 |
$15,745 |
D/D |
4,700 |
155,000 |
2.39 |
- |
|
| Edwards Mark G |
Director |
– • – |
2018-06-01 |
4 |
B |
$3.30 |
$990 |
D/D |
300 |
150,300 |
2.31 |
- |
|
| Asadorian Raffi |
Chief Financial Officer |
• – – |
2018-05-25 |
4 |
B |
$3.18 |
$15,923 |
D/D |
5,000 |
27,000 |
2.74 |
- |
|
| Three Arch Associates Iii Lp |
10% Owner |
– – • |
2018-05-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,367,041) |
0 |
|
- |
|
| Edwards Mark G |
Director |
– • – |
2017-11-14 |
4 |
B |
$1.90 |
$56,970 |
D/D |
30,000 |
150,000 |
2.39 |
- |
|
| Asadorian Raffi |
Chief Financial Officer |
• – – |
2017-11-13 |
4 |
B |
$1.94 |
$9,711 |
D/D |
5,000 |
12,000 |
2.74 |
- |
|
| Dasu Badri N |
Chief Engineering Officer |
• – – |
2017-10-19 |
4 |
OE |
$1.20 |
$45,000 |
D/D |
37,500 |
74,390 |
|
- |
|
| Hamel Lawrence G |
Chief Development Officer |
• • – |
2017-10-02 |
4 |
AS |
$5.29 |
$53,752 |
I/I |
(10,161) |
41,964 |
|
- |
|
| Hamel Lawrence G |
Chief Development Officer |
• • – |
2017-09-25 |
4 |
S |
$0.00 |
$0 |
I/I |
(13,827) |
68,504 |
|
- |
|
| Asadorian Raffi |
Chief Financial Officer |
• • – |
2017-09-11 |
4 |
B |
$3.24 |
$22,705 |
D/D |
7,000 |
7,000 |
2.74 |
- |
|
| Angotti Vincent J. |
Chief Executive Officer |
• • – |
2017-08-24 |
4 |
B |
$3.00 |
$45,000 |
D/D |
15,000 |
15,000 |
2.81 |
- |
|
| Edwards Mark G |
Director |
• • – |
2017-08-24 |
4 |
B |
$3.03 |
$14,520 |
D/D |
4,800 |
120,000 |
2.39 |
- |
|
| Edwards Mark G |
Director |
• • – |
2017-08-22 |
4 |
B |
$2.90 |
$580 |
D/D |
200 |
115,200 |
2.31 |
- |
|
| Palmer Pamela P |
Chief Medical Officer |
• • – |
2017-08-22 |
4 |
B |
$2.95 |
$29,487 |
D/D |
10,000 |
415,801 |
2.81 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2017-06-19 |
4 |
S |
$2.40 |
$2,100,000 |
I/I |
(875,000) |
4,533,728 |
|
- |
|
| Hamel Lawrence G |
Chief Development Officer |
• • – |
2017-04-10 |
4 |
A |
$0.00 |
$10,946 |
D/D |
16,001 |
80,354 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-09-29 |
4 |
S |
$3.88 |
$377,117 |
I/I |
(97,200) |
5,386,410 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-09-28 |
4 |
S |
$3.96 |
$472,380 |
I/I |
(119,300) |
5,483,610 |
|
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-09-15 |
4 |
S |
$3.63 |
$1,452,811 |
I/I |
(392,850) |
5,602,910 |
|
- |
|
| Rosen Howard B |
CEO |
• • – |
2016-05-13 |
4 |
B |
$3.26 |
$33,272 |
D/D |
10,206 |
50,000 |
2.81 |
- |
|
| Edwards Mark G |
Director |
• • – |
2016-05-12 |
4 |
B |
$3.05 |
$15,250 |
D/D |
5,000 |
115,000 |
2.39 |
- |
|
| Edwards Mark G |
Director |
• • – |
2016-05-11 |
4 |
B |
$3.15 |
$15,750 |
D/D |
5,000 |
110,000 |
2.39 |
- |
|
| Edwards Mark G |
Director |
• • – |
2016-05-10 |
4 |
B |
$3.25 |
$16,250 |
D/D |
5,000 |
105,000 |
2.39 |
- |
|
271 Records found
|
|
Page 7 of 11 |
|
|
0.07 (5.35%) 
